Press Releases



Mediclinic Intnl plc - Director/PDMR Shareholding

10/06/2020
RNS Number : 4539P
Mediclinic International plc
10 June 2020
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

10 June 2020

 

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

On 8 June 2020, Mr Jurgens Myburgh, Group Chief Financial Officer of Mediclinic International plc, acquired 7 500 shares in the Company at ZAR 63.94 per share. This purchase has been made in accordance with the Company's Remuneration Policy, whereby Mr Myburgh is required to maintain a minimum shareholding of 200% of his annual base compensation and until he has met that target, to purchase shares in the Company with 50% of the post-tax proceeds received from the deferred portion of awards made under the Short Term Incentive scheme and settled in cash. Mr Myburgh now owns a total of 90 500 shares in Mediclinic International plc.

 

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 

1.

Details of PDMR / persons closely associated with them ("PCA")

 

a)

Name

Mr Petrus Jurgens Myburgh

 

2.

Reason for the notification

 

a)

Position / status

Group Chief Financial Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Purchase of shares

 

 

c)

Price(s) and volume(s)

Price(s) per share

Volume(s)

ZAR 6388.00

386

ZAR 6388.00

364

ZAR 6388.00

500

ZAR 6389.00

1 321

ZAR 6389.00

500

ZAR 6393.00

268

ZAR 6395.00

500

ZAR 6396.00

500

ZAR 6400.00

500

ZAR 6400.00

1 052

ZAR 6400.00

1 609

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

7 500

 

ZAR 63.94 per share

 

 

e)

Date of the transaction

8 June 2020; 09:26 UTC

 

 

f)

Place of the transaction

Johannesburg Stock Exchange

 

 

 

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 1 June 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 21 outpatient clinics. Hirslanden operated 17 hospitals, three day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Caroline Emmet

+44 (0)20 7954 9548

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com 

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa 

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBLGDLCXGDGGC